Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain

Journal of Virology

Volumn 78, Issue 12, 2004, Pages 6344-6359

  Peden, Carmen S ^a   Burger, Corinna ^a   Muzyczka, Nicholas ^a   Mandel, Ronald J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS TYPE 2 ANTIBODY; ADENO ASSOCIATED VIRUS TYPE 2 VACCINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GREEN FLUORESCENT PROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS VACCINE;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS TYPE 2; ADENO ASSOCIATED VIRUS TYPE 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTYPE; SIGNAL TRANSDUCTION; VIRUS RECOMBINANT; VIRUS STRAIN; WILD TYPE;

ANIMALS; ANTIBODIES, VIRAL; BRAIN; CORPUS STRIATUM; DEPENDOVIRUS; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GREEN FLUORESCENT PROTEINS; IMMUNIZATION; IMMUNIZATION, SECONDARY; LUMINESCENT PROTEINS; NERVE GROWTH FACTORS; NEUTRALIZATION TESTS; PARVOVIRIDAE INFECTIONS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINATION, GENETIC; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 2642537522     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.12.6344-6359.2004     Document Type: Article

References (51)

1. Bartlett, J. S., R. Wilcher, and R. J. Samulski. 2000. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74:2777-2785.
2. Beck, S. E., L. A. Jones, K. Chesnut, S. M. Walsh, T. C. Reynolds, B. J. Carter, F. B. Askin, T. R. Flotte, and W. B. Guggino. 1999. Repeated delivery of adeno-associated virus vectors to the rabbit airway. J. Virol. 73:9446-9455.
3. Blacklow, N. R., M. D. Hoggan, and W. P. Rowe. 1968. Serologic evidence for human infection with adenovirus-associated viruses. J. Natl. Cancer Inst. 40:319-327.
4. Blacklow, N. R., M. D. Hoggan, M. S. Sereno, C. D. Brandt, H. W. Kim, R. H. Parrott, and R. M. Chanock. 1971. A seroepidemiologic study of adenovirus-associated virus infection in infants and children. Am. J. Epidemiol. 94:359-366.
5. Brockstedt, D. G., G. M. Podsakoff, L. Fong, G. Kurtzman, W. Mueller-Ruchholtz, and E. G. Engleman. 1999. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin. Immunol. 92:67-75.
6. Byrnes, A. P., J. E. Rusby, M. J. Wood, and H. M. Charlton. 1995. Adeno-virus gene transfer causes inflammation in the brain. Neuroscience 66:1015-1024.
7. Cartmell, T., T. Southgate, G. S. Rees, M. G. Castro, P. R. Lowenstein, and G. N. Luheshi. 1999. Interleukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain. J. Neurosci. 19:1517-1523.
8. Chirmule, N., K. Propert, S. Magosin, Y. Qian, R. Qian, and J. Wilson. 1999. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6:1574-1583.
9. Chirmule, N., W. Xiao, A. Truneh, M. A. Schnell, J. V. Hughes, P. Zoltick, and J. M. Wilson. 2000. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J. Virol. 74:2420-2425.
10. Corti, O., A. Sanchez-Capelo, P. Colin, N. Hanoun, M. Hamon, and J. Mallet. 1999. Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 96:12120-12125.
11. D'Agata, V., W. Zhao, and S. Cavallaro. 2000. Cloning and distribution of the rat parkin mRNA. Brain Res. Mol. Brain Res. 75:345-349.
12. Erles, K., P. Sebokova, and J. R. Schlehofer. 1999. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J. Med. Virol. 59:406-411.
13. Gash, D. M., Z. M. Zhang, A. Ovadia, W. A. Cass, A. Yi, L. Simmerman, D. Russell, D. Martin, P. A. Lapchak, F. Collins, B. J. Hoffer, and G. A. Gerhardt. 1996. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380:252-255.
14. Ge, Y., S. Powell, M. Van Roey, and J. G. McArthur. 2001. Factors influencing the development of an anti-factor IX (fIX) immune response following administration of adeno-associated virus-fIX. Blood 97:3733-3737.
15. Georg-Fries, B., S. Biederlack, J. Wolf, and H. zur Hausen. 1984. Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology 134:64-71.
16. Gill, S. S., N. K. Patel, G. R. Hotton, K. O'Sullivan, R. McCarter, M. Bunnage, D. J. Brooks, C. N. Svendsen, and P. Heywood. 2003. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9:589-595.
17. Grimm, D., A. Kern, K. Rittner, and J. A. Kleinschmidt. 1998. Novel tools for production and purification of recombinant viral vectors. Hum. Gene Ther. 9:2745-2760.
18. Halbert, C. L., E. A. Rutledge, J. M. Allen, D. W. Russell, and A. D. Miller. 2000. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J. Virol. 74:1524-1532.
19. Halbert, C. L., T. A. Standaert, M. L. Aitken, I. E. Alexander, D. W. Russell, and A. D. Miller. 1997. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J. Virol. 71:5932-5941.
20. Halbert, C. L., T. A. Standaert, C. B. Wilson, and A. D. Miller. 1998. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J. Virol. 72:9795-9805.
21. Hernandez, Y. J., J. Wang, W. G. Kearns, S. Loiler, A. Poirier, and T. R. Flotte. 1999. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J. Virol. 73:8549-8558.
22. Herrlinger, U., C. M. Kramm, K. S. Aboody-Guterman, J. S. Silver, K. Ikeda, K. M. Johnston, P. A. Pechan, R. F. Barth, D. Finkelstein, E. A. Chiocca, D. N. Louis, and X. O. Breakefield. 1998. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther. 5:809-819.
23. Janson, C., S. McPhee, L. Bilaniuk, J. Haselgrove, M. Testaiuti, A. Freese, D. J. Wang, D. Shera, P. Hurh, J. Rupin, E. Saslow, O. Goldfarb, M. Goldberg, G. Larijani, W. Sharrar, L. Liouterman, A. Camp, E. Kolodny, J. Samulski, and P. Leone. 2002. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum. Gene Ther. 13:1391-1412.
24. Kajiwara, K., A. P. Byrnes, H. M. Charlton, M. J. Wood, and K. J. Wood. 1997. Immune responses to adenoviral vectors during gene transfer in the brain. Hum. Gene Ther. 8:253-265.
25. Kessler, P. D., G. M. Podsakoff, X. Chen, S. A. McQuiston, P. C. Colosi, L. A. Matelis, G. J. Kurtzman, and B. J. Byrne. 1996. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. USA 93:14082-14087.
26. Kirik, D., C. Rosenblad, A. Björklund, and R. J. Mandel. 2000. Long-term rAAV mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 20:4686-4700.
27. Kordower, J. H., M. E. Emborg, J. Bloch, S. Y. Ma, Y. Chu, L. Leventhal, J. McBride, E. Y. Chen, S. Palfi, B. Z. Roitberg, W. D. Brown, J. E. Holden, R. Pyzalski, M. D. Taylor, P. Carvey, Z. Ling, D. Trono, P. Hantraye, N. Deglon, and P. Aebischer. 2000. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290:767-773.
28. Lo, W. D., G. Qu, T. J. Sferra, R. Clark, R. Chen, and P. R. Johnson. 1999. Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum. Gene Ther. 10:201-213.
29. Lowenstein, P. R. 2002. Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective. Trends Immunol. 23:23-30.
30. Luo, J., M. G. Kaplitt, H. L. Fitzsimons, D. S. Zuzga, Y. Liu, M. L. Oshinsky, and M. J. During. 2002. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298:425-429.
31. Mandel, R. J., K. G. Rendahl, S. K. Spratt, R. O. Snyder, L. K. Cohen, and S. E. Leff. 1998. Characterization of intrastriatal recombinant adeno-associated virus mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydroxylase I in a rat model of Parkinson's disease. J. Neurosci. 18:4271-4284.
32. Manning, W. C., S. Zhou, M. P. Bland, J. A. Escobedo, and V. Dwarki. 1998. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum. Gene Ther. 9:477-485.
33. Mastakov, M. Y., K. Baer, C. W. Symes, C. B. Leichtlein, R. M. Kotin, and M. J. During. 2002. Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J. Virol. 76:8446-8454.
34. Monahan, P. E., and R. J. Samulski. 2000. AAV vectors: is clinical success on the horizon? Gene Ther. 7:24-30.
35. Moskalenko, M., L. Chen, M. van Roey, B. A. Donahue, R. O. Snyder, J. G. McArthur, and S. D. Patel. 2000. Epitope mapping of human anti-adenoassociated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J. Virol. 74:1761-1766.
36. Peden, C. S., C. Burger, N. Muzyczka, and R. J. Mandel. 2003. The effects of pre-immunization to wt AAV on single and multiple administrations of rAAV in the brain. Mol. Ther. 7:S12.
37. Rosenblad, C., D. Kirik, and A. Björklund. 2000. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp. Neurol. 161:503-516.
38. Samulski, R. J., K. I. Berns, M. Tan, and N. Muzyczka. 1982. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc. Natl. Acad. Sci. USA 79:2077-2081.
39. Thomas, C. E., D. Birkett, I. Anozie, M. G. Castro, and P. R. Lowenstein. 2001. Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol. Ther. 3:36-46.
40. Thomas, C. E., G. Schiedner, S. Kochanek, M. G. Castro, and P. R. Lowenstein. 2000. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc. Natl. Acad. Sci. USA 97:7482-7487.
41. Thomas, C. E., G. Schiedner, S. Kochanek, M. G. Castro, and P. R. Lowenstein. 2001. Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum. Gene Ther. 12:839-846.
42. West, M. J., L. Slomianka, and H. J. Gundersen. 1991. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 231:482-497.
43. Wu, P., W. Xiao, T. Conlon, J. Hughes, M. Agbandje-McKenna, T. Ferkol, T. Flotte, and N. Muzyczka. 2000. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74:8635-8647.
44. Xiao, W., N. Chirmule, M. A. Schnell, J. Tazelaar, J. V. Hughes, and J. M. Wilson. 2000. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. Mol. Ther. 1:323-329.
45. Xiao, X., J. Li, and R. J. Samulski. 1996. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 70:8098-8108.
46. Xiao, X., J. Li, and R. J. Samulski. 1998. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72:2224-2232.
47. Xu, L., T. Daly, C. Gao, T. R. Flotte, S. Song, B. J. Byrne, M. S. Sands, and K. Parker Ponder. 2001. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum. Gene Ther. 12:563-573.
48. Zaiss, A. K., Q. Liu, G. P. Bowen, N. C. Wong, J. S. Bartlett, and D. A. Muruve. 2002. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J. Virol. 76:4580-4590.
49. Zolotukhin, S., B. J. Byrne, E. Mason, I. Zolotukhin, M. Potter, K. Chesnut, C. Summerford, R. J. Samulski, and N. Muzyczka. 1999. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6:973-985.
50. Zolotukhin, S., M. Potter, I. Zolotukhin, Y. Sakai, S. Loiler, T. J. Fraites, Jr., V. A. Chiodo, T. Phillipsberg, N. Muzyczka, W. W. Hauswirth, T. R. Flotte, B. J. Byrne, and R. O. Snyder. 2002. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28:158-167.
51. Zufferey, R., J. E. Donello, D. Trono, and T. J. Hope. 1999. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73:2886-2892.